TABLE 1:

Survival after baseline MR imaging as a function of patient age, tumor histologic diagnosis, enhancement, and maximal nCBV values in 19 patients with follow-up data

Astrocytoma WHO Grade	Age (y)	Enhancement	nCBV	Survival (mo)
II/IV^*	31	No	0.4	102
II/IV^*	23	No	0.8	85
II/IV^*	38	No	0.9	74
II/IV	25	Yes	0.9	103
II/IV^*	51	No	2.1	82
II/IV^*	37	No	2.3	86
III/IV	37	No (trace)	1.6	10
III/IV	71	Yes	1.7	42
IV/IV	52	Yes	1.7	12
IV/IV	69	No	2.2	27
IV/IV	65	Yes	2.3	2
IV/IV	42	No	2.5	24
IV/IV	82	Yes	2.7	5
IV/IV	57	Yes	2.8	14
IV/IV	66	Yes	2.9	4
IV/IV	58	Yes	3.3	26
IV/IV	87	Yes	3.8	5
IV/IV	53	Yes	5.8	16
III/IV	12	Yes	7.3	8

Note.—Survival is sorted by ascending values of nCBV for both the low-grade (II/IV) and high-grade (III/IV and IV/IV) tumor groups.
* Indicates patients still alive at the time of most recent follow-up.